| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S1040-8428(03)00082-9 |
| P698 | PubMed publication ID | 12900012 |
| P50 | author | Josep Tabernero Caturla | Q37387600 |
| P2093 | author name string | Baselga J | |
| de Wit R | |||
| Albanell J | |||
| Bellmunt J | |||
| Albiol S | |||
| P2860 | cites work | Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. | Q27824766 |
| Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study | Q28139358 | ||
| Phase II trial of paclitaxel plus gemcitabine in patients with locally advanced or metastatic non-small-cell lung cancer. | Q31960257 | ||
| Paclitaxel and carboplatin in patients with metastatic transitional cell cancer of the urinary tract | Q33328290 | ||
| Gemcitabine plus cisplatin, an active regimen in advanced urothelial cancer: a phase II trial of the National Cancer Institute of Canada Clinical Trials Group | Q33330628 | ||
| Weekly gemcitabine and cisplatin combination therapy in patients with transitional cell carcinoma of the urothelium: a phase II clinical trial | Q33331273 | ||
| Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. | Q33334087 | ||
| Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer | Q33337149 | ||
| Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network | Q33337751 | ||
| Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. | Q33340282 | ||
| Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer | Q33341273 | ||
| M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced carcinoma of the bladder. The French Federation of Cancer Centers experience | Q33376563 | ||
| Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group | Q33488031 | ||
| Dose-intensification of MVAC with recombinant granulocyte colony-stimulating factor as initial therapy in advanced urothelial cancer | Q33489195 | ||
| Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study | Q33492710 | ||
| Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma | Q33499366 | ||
| Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). | Q33500303 | ||
| Phase II study of single-agent gemcitabine in previously untreated patients with metastatic urothelial cancer | Q33500776 | ||
| Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer | Q33501053 | ||
| Evaluation of epidermal growth factor receptor, transforming growth factor alpha, epidermal growth factor and c-erbB2 in the progression of invasive bladder cancer | Q73174777 | ||
| Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional-cell carcinoma of the urothelial tract | Q73445663 | ||
| Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q73494793 | ||
| Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial | Q73603362 | ||
| Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer | Q73719687 | ||
| Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma | Q73872746 | ||
| Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European | Q73881573 | ||
| Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation | Q73897079 | ||
| Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma | Q74545986 | ||
| Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study | Q77435874 | ||
| Preliminary results of M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for transitional cell carcinoma of the urothelium | Q93606365 | ||
| Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen | Q33501448 | ||
| Paclitaxel and carboplatin in patients with metastatic urothelial cancer: results of a phase II trial | Q33503299 | ||
| Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial | Q33503343 | ||
| A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer | Q33504597 | ||
| Oral piritrexim, an effective treatment for metastatic urothelial cancer | Q34360273 | ||
| Angiogenic factors and bladder cancer | Q34486214 | ||
| Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis | Q35979121 | ||
| Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients | Q36115695 | ||
| Survival of patients with advanced urothelial cancer treated with cisplatin-based chemotherapy | Q36136586 | ||
| Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study | Q40625649 | ||
| Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder | Q40658274 | ||
| Escalated MVAC with or without recombinant human granulocyte-macrophage colony-stimulating factor for the initial treatment of advanced malignant urothelial tumors: results of a randomized trial | Q40680796 | ||
| Escalated dosages of methotrexate, vinblastine, doxorubicin, and cisplatin plus recombinant human granulocyte colony-stimulating factor in advanced urothelial carcinoma: an Eastern Cooperative Oncology Group trial | Q40704537 | ||
| A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study | Q40731377 | ||
| Eastern Cooperative Oncology Group phase II trial of ifosfamide in the treatment of previously treated advanced urothelial carcinoma | Q40905847 | ||
| Phase I/II study of paclitaxel, carboplatin, and methotrexate in advanced transitional cell carcinoma: a well-tolerated regimen with activity independent of p53 mutation | Q41726923 | ||
| Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional-cell carcinoma: the importance of survival as a clinical trial end point | Q41747152 | ||
| Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse | Q43419722 | ||
| A feasibility study of carboplatin with fixed dose of gemcitabine in "unfit" patients with advanced bladder cancer | Q43777231 | ||
| Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition | Q43843455 | ||
| Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy | Q44578641 | ||
| Accumulation of nuclear p53 and tumor progression in bladder cancer. | Q45977663 | ||
| M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium | Q48104435 | ||
| The role of p53, MDM2 and c-erb B-2 oncoproteins, epidermal growth factor receptor and proliferation markers in the prognosis of urinary bladder cancer. | Q54143980 | ||
| P-glycoprotein expression in primary and metastatic transitional cell carcinoma of the bladder. | Q54192269 | ||
| An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. | Q54214610 | ||
| Cisplatin, methotrexate, and vinblastine (CMV): an effective chemotherapy regimen for metastatic transitional cell carcinoma of the urinary tract. A Northern California Oncology Group study. | Q54418734 | ||
| Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group | Q57905078 | ||
| A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors | Q68514585 | ||
| Phase III comparison of cisplatin alone versus cisplatin, doxorubicin and cyclophosphamide in the treatment of bladder (urothelial) cancer: a Southeastern Cancer Study Group trial | Q68945079 | ||
| Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours | Q69856767 | ||
| Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy | Q70113435 | ||
| Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study | Q71067477 | ||
| Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy | Q71667709 | ||
| Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in the treatment of refractory urothelial malignancies | Q71752197 | ||
| Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC | Q72240687 | ||
| Carboplatin-based chemotherapy for bladder cancer | Q72559643 | ||
| Taxol and taxotere in bladder cancer: in vitro activity and urine stability | Q72672232 | ||
| Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy | Q73042239 | ||
| Bcl-2 expression identifies patients with advanced bladder cancer treated by radiotherapy who benefit from neoadjuvant chemotherapy | Q73166904 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 195-206 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Critical Reviews in Oncology Hematology | Q15724423 |
| P1476 | title | New drugs and new approaches in metastatic bladder cancer | |
| P478 | volume | 47 |
| Q36334879 | Adjuvant chemotherapy for bladder cancer |
| Q36729145 | Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. |
| Q79317050 | Feasiblity study of gemcitabine and cisplatin administered every two weeks in patients with advanced urothelial tumors and impaired renal function |
| Q79316299 | Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a new standard of care? |
| Q35173073 | Novel approaches with targeted therapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family |
| Q36619428 | State-of-the-art management of metastatic disease at initial presentation or recurrence |
| Q37290448 | Targeted therapies in the management of metastatic bladder cancer |
| Q38337192 | The route to personalized medicine in bladder cancer: where do we stand? |
Search more.